Test Price
2,800 AEDโ Home Collection Available
WT1 Gene (Wilms Tumor Type 1, Familial) Genetic Test in UAE | 2,800 AED | Next-Generation Sequencing
Executive Summary & Core Metrics
โ Accuracy Guarantee: 99.9% diagnostic sensitivity via ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139) accredited sequencing.
โ Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM.
โ Clinical Guidance: Complimentary telephonic post-test result interpretation by a Consultant Medical Genetics specialist.
โ Insurance: Direct billing verification via WhatsApp +971 54 548 8731.
โ Test Type: Single-gene NGS analysis for familial Wilms tumor predisposition.
โ Specimen: Whole blood, FTA card, or extracted DNA.
โ Turnaround Time: 3-4 weeks from sample receipt.
โ DHA Licensed: Facility License No. 1143, Dubai Healthcare City.
Test Overview & Methodology
This advanced next-generation sequencing (NGS) test analyzes the entire coding region and splice-site junctions of the WT1 gene to detect germline pathogenic variants associated with familial Wilms tumor type 1, an inherited paediatric kidney cancer predisposition syndrome. The assay achieves deep coverage across all 10 coding exons and flanking intronic regions, enabling identification of single-nucleotide variants, small insertions and deletions, and copy-number changes with high analytical sensitivity.
| Feature | Our Test (NGS) | Closest Alternative (Single-Gene Sanger) |
|---|---|---|
| Precision | 99.9% analytical sensitivity and coverage of all coding exons plus splice sites | ~95% sensitivity; may miss deep intronic or regulatory variants |
| Methodology | Illumina-based NGS with orthogonal Sanger confirmation of all pathogenic findings | Sanger sequencing of selected exons only; limited throughput |
| Turnaround Time | 3-4 weeks | 6-8 weeks due to sequential exon-by-exon analysis |
Physician Insight & Safety Protocols
Lina Osama Zaki Quteineh | Consultant Medical Genetics | DHA Registration ID: 9294403: "The WT1 gene test identifies hereditary susceptibility for Wilms tumor, not active malignancy. A positive result must be interpreted alongside renal imaging, family pedigree analysis, and clinical examination. I personally review each case to ensure families receive accurate risk assessment and evidence-based surveillance recommendations."
Medication Advisory
Do not discontinue any prescribed medication or initiate new treatments without consulting your referring physician. This genetic test is for risk assessment only and does not replace standard oncologic care.
Exclusion Criteria & Emergency Red Flags
- This test is not suitable for diagnosis of active Wilms tumor; use only for hereditary risk assessment in asymptomatic individuals with family history.
- Unsuitable for individuals unable to provide informed consent or without pre-test genetic counselling from a qualified genetics professional.
- Seek immediate emergency care if the child develops a palpable abdominal mass, persistent flank pain, visible blood in urine (hematuria), unexplained fever, or new-onset hypertension.
Patient FAQ & Clinical Guidance
1. What does the WT1 gene test for familial Wilms tumor detect?
The WT1 gene test using NGS detects inherited pathogenic variants that confer elevated risk for Wilms tumor type 1 familial predisposition. Identifying a pathogenic variant enables early surveillance with renal ultrasound, risk-reducing clinical management, and informed family planning.
2. Who should consider undergoing this genetic test?
Individuals with a family history of Wilms tumor, early-onset kidney cancer, bilateral or multifocal Wilms tumor, or a known WT1 pathogenic variant in a first-degree relative are ideal candidates. Pre-test genetic counselling is mandatory to discuss implications for the patient and at-risk relatives.
3. How is the sample collected and what is the turnaround time?
A simple peripheral blood draw (3-5 mL in EDTA tube), FTA card spot, or extracted genomic DNA is collected by our certified phlebotomist at your home or at our DHCC collection centre. Results are reported within 3-4 weeks from sample receipt.
4. How is my genetic data protected under UAE law?
Your genetic information is handled in strict compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All data is encrypted, access-controlled, and never shared without your explicit written consent.
5. What happens if the test result is positive?
A positive result indicates a germline pathogenic variant in WT1. Our Consultant Medical Genetics specialist will provide a detailed telephonic consult to explain the implications, coordinate renal surveillance imaging, and discuss cascade testing for at-risk family members. Referral to a paediatric oncologist is arranged if clinically indicated.
UAE Regulatory & Data Privacy Adherence
This genetic test is performed in full compliance with the UAE legal framework governing medical genetics and health data privacy. All processes adhere to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) for the collection, storage, and processing of genetic information. Health information technology systems comply with Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and informed consent protocols follow Federal Decree-Law No. 4 of 2016 on Medical Liability. DNA Labs UAE holds DHA Facility License No. 1143 and maintains ISO 9001:2015 certification for quality management in genetic testing services.
Clinical & Logistical Metadata
| Test Name | WT1 Gene (Wilms Tumor Type 1, Familial) Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3-4 Weeks |
| Sample Type / Matrix | Whole Blood (EDTA), FTA Card, or Extracted Genomic DNA |
| Methodology Used | Next-Generation Sequencing (NGS) on Illumina Platform with Orthogonal Sanger Confirmation |
| ICD-10-CM Code | Z15.09 (Genetic susceptibility to other malignant neoplasm) |
| LOINC Code | 93716-8 (WT1 gene mutation analysis in Blood or Tissue by Sequencing) |
| DHA Facility License & Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians